Drugs / DA-2802
last change Jul 2019 re-read 2 minutes ago

DA-2802

Developed for
chronic hepatitis B virus infection
Investigated by
Dong-A ST Co., Ltd.

Trials 2 · a red edge is where a trial was stopped

20162017201820192020202120222023202420252026
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 11 trial
Phase 1 NCT02557594 Oct → Nov 2015 Dong-A ST Co., Ltd. Completed No outcome recorded
Phase 31 trial
Phase 3 NCT02967939 Mar 2017 → Jan 2019 chronic hepatitis B virus infection Dong-A ST Co., Ltd. Completed No outcome recorded

Evidence & citations 2 cited values

Every value below carries the sentence it was read from. 2 sources stand behind the page.

FieldValueCited text
Known as DA-2802 ClinicalTrials.gov intervention name — accepted as the source's own label NCT02967939
1

NCT02557594

Route Oral “single oral dose” NCT02557594